Vertiginous syndrome

The BEACH program (Bettering the Evaluation and Care of Health) shows that management of vertiginous syndrome occurred three times per 1000 encounters from January 2006 to December 2007. This suggests that general practitioners manage vertiginous syndrome approximately 350,000 times nationally each year.

The 652 occurrences of vertiginous syndrome recorded over the 2 year period can be divided into benign positional vertigo (38.7%), labyrinthitis (31.9%), Meniere disease (17.4%) and vestibular disorders (12.1%).

Management of vertiginous syndrome was significantly more common among female patients (0.40 per 100 encounters) than male patients (0.26 per 100). The rate rose significantly by age of patient and peaked in the 65–74 years age group (Figure 1).

Rates of other problems managed at the encounter were lower than average. These comorbidities reflected the older age distribution of patients with vertiginous syndrome; with hypertension, oesophageal disease and lipid disorders most commonly managed.

Medication prescribing rates, at 67.3 per 100 vertiginous syndrome problems managed, were average for BEACH. The most commonly prescribed medication, prochlorperazine, accounted for more than three-quarters of all medications recorded for vertiginous syndrome. Betahistine accounted for another 15%, with the remainder made up of various groups including diuretics and analgesics.

Total clinical and procedural treatments, referrals and imaging orders were provided at rates close to the average for BEACH encounters. However, specific treatments such as therapeutic exercises, referrals to ear, nose and throat (ENT) specialists, and orders for computerised tomography scans of brain and head were provided at higher rates than normal. The pathology ordering rate of 16.4 was lower than that for all problems managed in BEACH (28.6).

Table 1 shows details of the management of vertiginous syndrome.

Conflict of interest: none.

Acknowledgments

The authors thank the GP participants in the BEACH program and all members of the BEACH team. Financial contributors to BEACH in 2006 and 2007: Australian Institute of Health and Welfare; National Prescribing Service; AstraZeneca Pty Ltd (Australia); Janssen-Cilag Pty Ltd; Merck, Sharp and Dohme (Australia) Pty Ltd; Pfizer Australia; Abbott Australasia; Sanofi-Aventis Australia Pty Ltd; Roche Products Pty Ltd.